Stock events for Dyadic International, Inc. (DYAI)
Dyadic International, Inc.'s stock price has been impacted by several events in the past six months. As of February 20, 2026, the share price was $0.80, a 42.39% decrease from $1.38 on February 24, 2025. Q3 2025 earnings reported an EPS of -$0.06, missing forecasts by 20%, and revenue of $1.165 million, falling 22.67% below expectations, leading to a 7.42% drop in shares in after-hours trading. Q2 2025 revenue was $970,000, surpassing estimates, but EPS was -$0.06, resulting in a -2.44% decline in after-hours trading. The company rebranded as Dyadic Applied BioSolutions in mid-2025, shifting to a commercially focused enterprise. Recent commercial launches include AlbuFree™ DX with Proliant Health & Biologicals and animal-origin-free Recombinant DNase I with Fermbox Bio. Dyadic Applied BioSolutions and Inzymes ApS also announced planned 2026 commercialization of recombinant non-animal bovine chymosin. Fintel reported price target increases for Dyadic International (DYAI) by 25.00% to $5.10 on December 6, 2025, and by 40.00% to $7.14 on January 14, 2026.
Demand Seasonality affecting Dyadic International, Inc.’s stock price
Information regarding the specific demand seasonality for Dyadic International, Inc.'s products and services is not publicly available.
Overview of Dyadic International, Inc.’s business
Dyadic International, Inc., now Dyadic Applied BioSolutions, is a global biotechnology company specializing in large-scale protein manufacture. It operates in the pharmaceuticals & biotech sector, focusing on industrial enzymes and proteins, utilizing its C1 and Dapibus™ platforms. The C1 platform, based on the fungus Thermothelomyces heterothallica, is used for pharmaceutical applications like vaccines and therapeutics. The Dapibus platform is designed for low-cost protein manufacture for non-pharmaceutical applications, including life sciences, food and nutrition, and bio-industrial markets. Dyadic is also developing DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate, which is in Phase 1 clinical trial.
DYAI’s Geographic footprint
Dyadic International, Inc. is a global biotechnology company headquartered in Jupiter, Florida, with R&D operations in The Netherlands. It has international collaborations, including agreements with VTT Technical Research Centre of Finland, Rubic One Health in South Africa, and Abic Biological Laboratories Ltd.
DYAI Corporate Image Assessment
Dyadic International, Inc.'s brand reputation has been shaped by its rebranding as Dyadic Applied BioSolutions, marking a shift from research-driven to commercially focused. This rebrand emphasizes its growing commercial biotechnology capabilities and expanding portfolio. The company aims to be seen as focused on execution and market traction, reflected in a redesigned website and updated communications.
Ownership
Dyadic International, Inc. has a diverse ownership structure, including institutional investors, individual insiders, and the general public. Institutional investors own 27.95% of the stock, with major holders including Apis Capital Advisors, LLC, and Vanguard Group Inc. The CEO, Mark A. Emalfarb, is a significant individual shareholder, owning 37,361,914 shares, representing 103.24% of the company according to one source, and 29% of shares outstanding according to another. The general public owns 54% of Dyadic International.
